Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies - Howard, C; Noe, A; Skerjanec, A (Cardiovascular diabetology, 2014)
et al.